Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Lab-on-a-Chip Uses Bacteria to Help Transport Biological Cargo

Researchers have used light patterns to control the swimming speed of bacteria and direct them to form different shapes, according to a new study (“Dynamic density shaping of photokinetic E. coli”) in eLife. Controlling bacteria in this way means it could be p

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers have used light patterns to control the swimming speed of bacteria and direct them to form different shapes, according to a new study (“Dynamic density shaping of photokinetic E. coli”) in eLife. Controlling bacteria in this way means it could be possible to use them as microbricks for building the next generation of microscopic devices. For example, they could be made to surround a larger object such as a machine part or a drug carrier, and then used as living propellers to transport it where it is needed.

“Many motile microorganisms react to environmental light cues with a variety of motility responses guiding cells towards better conditions for survival and growth. The use of spatial light modulators could help to elucidate the mechanisms of photo-movements while, at the same time, providing an efficient strategy to achieve spatial and temporal control of cell concentration. Here we demonstrate that millions of bacteria, genetically modified to swim smoothly with a light controllable speed, can be arranged into complex and reconfigurable density patterns using a digital light projector,” write the investigators.

“We show that a homogeneous sea of freely swimming bacteria can be made to morph between complex shapes. We model non-local effects arising from memory in light response and show how these can be mitigated by a feedback control strategy resulting in the detailed reproduction of grayscale density images.”

Escherichia coli (E. coli) bacteria can swim a distance of ten times their length in a second. They have propellers that are powered by a motor, and they usually recharge this motor by a process that needs oxygen. Recently, scientists found a protein (proteorhodopsin) in ocean-dwelling bacteria that allows them to power their propellers using light. By engineering other types of bacteria to have this protein, it is possible to place a “solar panel” on every bacterial cell and control its swimming speed remotely with light.

“Much like pedestrians who slow down their walking speed when they encounter a crowd, or cars that are stuck in traffic, swimming bacteria will spend more time in slower regions than in faster ones,” explains lead author Giacomo Frangipane, Ph.D., postdoctoral scientist at Rome University, Italy. “We wanted to exploit this phenomenon to see if we could shape the concentration of bacteria using light.”

To do this, Dr. Frangipane and his team sent light from a projector through a microscope lens, shaping the light with high resolution, and explored how E. coli bacteria alter their speed while swimming through regions with varying degrees of illumination.

They projected the light uniformly onto a layer of bacterial cells for five minutes, before exposing them to a more complex light pattern—a negative image of the Mona Lisa. They found that bacteria started to concentrate in the dark regions of the image while moving out from the more illuminated areas. After four minutes, a recognizable bacterial replica of Leonardo da Vinci's painting could be seen, with brighter areas corresponding to regions of accumulated bacterial cells.

Although the shape formed by the bacteria was recognizable, the team found that the engineered E. coli were slow to respond to variations in light, which led to a blurred formation of the target shape. To remedy this, they used a feedback control loop where the bacterial shape is compared to the target image every 20 seconds, and the light pattern is updated accordingly. This generated an optimal light pattern that shaped cell concentration with much higher accuracy. The result is a photokinetic bacterial cell layer that can be turned into an almost perfect replica of a complex black-and-white target image.

“We have shown how the suspension of swimming bacteria could lead to a new class of light-controllable active materials whose density can be shaped accurately, reversibly, and quickly using a low-power light projector,” says Roberto Di Leonardo, Ph.D., associate professor in the department of physics at Rome University. “With further engineering, the bacteria could be used to create solid biomechanical structures or novel microdevices for the transport of small biological cargoes inside miniaturized laboratories.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →